Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned ...
(PR-inside.com) Independent Data Monitoring Committee recommends ASPIRE continue without modification; no safety concerns identified Fully enrolled 378-patient trial advances toward 52-week readout STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / October 22, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Na…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


